Ramsay Health Care Ltd Share Price and Fundamentals (RHC)

Overview

Ramsay Health Care Ltd is one of Australia’s better-known healthcare operators, running hospitals for public and private patients across Australia and overseas. For investors, the appeal is the defensive character of hospital demand, but the share price also reflects the realities of a capital-intensive business where earnings quality, pricing power and operating execution matter just as much as scale. At A$45.00, the stock sits close to its 52-week high of A$45.62 and well above the 52-week low of A$30.10, underlining how strongly sentiment has recovered over the past year.

Ramsay Health Care has built a sizeable footprint in medical care facilities, with revenue of A$18.6B and a market capitalisation of A$10.3B. The company’s business is centred on hospital operations, which typically benefit from the steady underlying demand associated with healthcare services rather than the more cyclical forces that affect many other sectors. That said, hospital operators still face pressure from labour costs, regulation, reimbursement settings and the need to keep investing in facilities and equipment. The latest figures point to revenue growth of 9.70%, suggesting the business is still expanding, while the dividend yield of 1.84% adds a modest income component for shareholders. The reported EPS of A$1.26 and dividend per share of A$0.825 help frame the current earnings and payout profile, although the headline profit margin of 156.00% appears unusually high and should be read cautiously in the context of company reporting mechanics and one-off items.

Key facts

Price and trend

Valuation

On the supplied numbers, Ramsay Health Care is priced on a P/E ratio of 35.44 and a PEG ratio of 2.15, which suggests the market is already assigning a meaningful premium to the company’s earnings base and growth profile. The share price of A$45.00 is also above both the 50-day moving average of A$42.79 and the 200-day moving average of A$38.75, showing the stock has been trading with solid momentum relative to recent trends. Against the latest target price of A$43.96, the current price is 2.32% from that level, which is useful context but not a standalone valuation call. Overall, the market appears to be paying for Ramsay’s defensive industry position and scale, while also demanding evidence that growth can be sustained without compromising profitability or balance-sheet flexibility.

Profitability and growth

Analyst view

The technical backdrop is constructive rather than euphoric. Ramsay Health Care is trading 5.16% above its 50-day average and 16.13% above its 200-day average, indicating the share price has held a stronger trend across both the medium and longer term. Its beta of 0.585 suggests the stock has historically been less volatile than the broader market, which fits the profile of a healthcare operator with relatively stable demand characteristics. Even so, the share price is now close to the top of its 52-week range, so future gains may depend more on operating delivery and margin consistency than on re-rating alone. For Australian investors, that combination of defensive sector exposure, moderate dividend yield and a premium earnings multiple makes Ramsay a company where business execution remains central to the investment case.

ETFs Featuring RHC

Risks

The main risks sit in the operating model rather than in demand alone. Hospitals are expensive to run, and Ramsay must manage staffing, occupancy, funding arrangements and ongoing capital requirements while preserving returns. The current valuation leaves less room for disappointment if earnings growth slows or if costs rise faster than revenue. The share price is also already near its 52-week high, so any softer trading update could weigh on sentiment. While the stock’s beta is relatively low, that does not remove the possibility of earnings volatility from regulation, reimbursement changes or overseas operating conditions. The dividend yield is present, but it is not especially high, so the stock is being valued more for its healthcare franchise and scale than for income alone.

FAQ